 

Active Ingredient: Aspirin 

 

Dosage Form; Route: Capsule; oral 

 

Recommended Studies: Two studies 

 

1. Type of study: Fasting 


Design: Single-dose, two-way crossover in vivo 

Strength: 325 mg 

Subjects: Healthy males and nonpregnant females, general population 

Additional comments: None 

 

 

2. Type of study: Fed 


Design: Single-dose, two-way crossover in vivo 

Strength: 325 mg 

Subjects: Healthy males and nonpregnant females, general population 

Additional comments: None 

 

 

Analytes to measure: Acetylsalicylic acid and its active metabolite, salicylic acid, in plasma 

 

Submit the metabolite data as supportive evidence of comparable therapeutic outcome. For the 
metabolite, the following data should be submitted: individual and mean concentrations, 
individual and mean pharmacokinetic parameters, and geometric means and ratios of means for 
AUC and Cmax. 

 

Bioequivalence based on (90% CI): Acetylsalicylic acid 

 

Waiver request of in vivo testing: Not applicable 

 

Dissolution test method and sampling times: The dissolution information for this drug 
product can be found on the FDA-Recommended Dissolution Methods Web site, available to the 
public at the following location: http://www.accessdata.fda.gov/scripts/cder/dissolution/. 
Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and 
reference products. Specifications will be determined upon review of the abbreviated new drug 
application (ANDA). 


